Now PlayingEP. 1 Preferred Induction Regimen for Transplant-Eligible Patients with Newly-diagnosed Multiple Myeloma
November 11th, 2026LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCCThomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.Read more
November 11th, 2026Governor Hochul Announces Historic Cancer Care Training Partnership Between New York and Puerto Rico Medical Institutions at SOMOS Conference 2026Gov. Hochul unveils a cell and gene therapy fellowship between Roswell Park and San Juan City Hospital to train Puerto Rico physicians in advanced cancer care.Read more
November 11th, 2026First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian CancerRetrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.Read more
November 11th, 2026Sonrotoclax-Based Regimens Elicit Responses in Relapsed/Refractory MCLA meta-analysis of 4 sonrotoclax cohorts showed consistent response activity and low tumor lysis rates in heavily pretreated mantle cell lymphoma.Read more
November 11th, 2026Breast Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.Read more
November 10th, 2026Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate CancerExperts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.Read more
November 10th, 2026Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker AnalysisExploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.Read more
November 10th, 2026FDA Approves Pimicotinib for Symptomatic TGCTThe FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.Read more